

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

CLARIFICATION ANNOUNCEMENT

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company has noticed the price movement of the shares of the Company and certain media reports related to the progress of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “**Ad5-nCoV**”).

The Company hereby makes following statements and clarifications to prevent the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company from being misled:

1. The Company received the notification letter about granting of the patent "a recombinant novel coronavirus vaccine using human replication-deficient adenovirus as a carrier" (一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗) on August 11, 2020. The patent application was jointly filed by Beijing Institute of Biotechnology, Academy of Military Medical Sciences and the Company; and
2. Phase II clinical trial for Ad5-nCoV has been completed. Please refer to the announcement published on July 21, 2020 by the Company for details of the research findings. The Company is currently liaising with several countries and plan to drive the international multi-center phase III clinical trial for Ad5-nCoV as soon as possible. As at the date of this announcement, enrollment of phase III clinical trial has not started.

Save as disclosed in this announcement, after having made all reasonable enquiries with the Company, the Board of Directors confirms that it is not aware of any other information which must be announced to avoid a false market in the Company's securities or any inside information that needs to be disclosed under the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) under Part XIVA of the Securities and Futures Ordinance.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The safety and efficacy of Ad5-nCoV are subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or commercialize Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 18, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.